Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
8(62%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
5
38%
Ph phase_2
3
23%
Ph phase_3
5
38%

Phase Distribution

5

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
5(38.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

8

trials recruiting

Total Trials

13

all time

Status Distribution
Active(10)
Completed(3)

Detailed Status

Recruiting8
Completed3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
13
Active
8
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (38.5%)
Phase 23 (23.1%)
Phase 35 (38.5%)

Trials by Status

recruiting862%
not_yet_recruiting215%
completed323%

Recent Activity

8 active trials
Showing 5 of 13
recruitingphase_3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

NCT07353931
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190
recruitingphase_2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608
recruitingphase_3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07353931Phase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Recruiting
NCT07282600Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Recruiting
NCT07392190Phase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Recruiting
NCT07589608Phase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Recruiting
NCT07369011Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
NCT07321886Phase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Recruiting
NCT07738614Phase 1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Not Yet Recruiting
NCT07215559Phase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Recruiting
NCT07665879Phase 1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Recruiting
NCT07701083Phase 1

A Study of Eloralintide (LY3841136) in Healthy Participants

Not Yet Recruiting
NCT06230523Phase 2

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Completed
NCT06916065Phase 1

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

Completed
NCT06916091Phase 1

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13